Quanterix (QTRX) AI Stock Analysis

• Market Cap: $242.09M
• Dividend Yield: N/A
• Average Volume (3M): 509.80K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.44
• Revenue Growth: -2.69%
• EPS Growth: -149.18%
• Country: US
• Employees: 471
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.73
• Shares Outstanding: 46,465,916
• 10 Day Avg. Volume: 461,526
• 30 Day Avg. Volume: 509,801
• PEG Ratio: -0.65
• Price to Book (P/B): 1.24
• Price to Sales (P/S): 2.97
• P/FCF Ratio: -10.58
• Enterprise Value/Market Cap: 0.14
• Enterprise Value/Revenue: 0.26
• Enterprise Value/Gross Profit: 0.50
• Enterprise Value/Ebitda: -0.35
• 1Y Price Target: $6.00
• Price Target Upside: -17.36% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 61 Neutral
• Price Target: $8.00 ▲(10.19% Upside)

Quanterix's stock score is primarily influenced by its financial challenges, despite strong technical momentum. The company's ongoing losses and cash flow issues weigh heavily on its valuation. However, positive developments from the earnings call and technical indicators provide some optimism for future growth.

Positive Factors

Revenue Growth

The consistent revenue growth indicates strong market demand and successful execution of strategic initiatives, enhancing long-term business prospects.

Cash Position

A strong cash position with no debt enhances financial stability, providing flexibility to invest in growth opportunities and withstand market fluctuations.

Innovation in Diagnostics

Significant R&D investment underscores a commitment to innovation, potentially leading to new product offerings and competitive advantages in diagnostics.

Negative Factors

Profitability Challenges

Persistent profitability issues indicate operational inefficiencies, which could hinder long-term financial health and ability to reinvest in the business.

Decline in Core Simoa Revenue

A significant decline in core product revenue suggests challenges in maintaining market share, which could impact future growth and profitability.

Weakness in Key Markets

Weakness in key markets like academia and pharma may limit revenue potential and growth opportunities, affecting long-term strategic positioning.

Quanterix Business Overview & Revenue Model

Company Description

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

How the Company Makes Money

Quanterix generates revenue primarily through the sale of its Simoa platforms, consumables, and related services. Key revenue streams include the direct sales of instruments and assay kits to research institutions, pharmaceutical companies, and clinical laboratories. Additionally, the company earns revenue from service contracts and collaborations with pharmaceutical companies for drug development and biomarker discovery. Strategic partnerships with organizations in the biopharmaceutical sector enhance its market reach and contribute to its earnings, as these collaborations often involve joint research projects and technology licensing agreements.

Quanterix Financial Statement Overview

Summary

Quanterix faces significant financial challenges, with negative net profit margins and cash flows indicating operational inefficiencies. Despite a strong equity base and some revenue growth, profitability and cash flow management are major concerns.

Income Statement

Quanterix's income statement reveals a challenging financial position. The company has shown some revenue growth with a TTM increase of 3.88%, but profitability remains a significant issue. Gross profit margins are relatively healthy at 55.54% TTM, yet net profit margins are deeply negative at -56.23% TTM, indicating substantial losses. EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges. The company needs to address its cost structure to improve profitability.

Balance Sheet

The balance sheet of Quanterix shows a moderate financial position. The debt-to-equity ratio is low at 0.12 TTM, suggesting manageable leverage. However, the return on equity is negative at -22.07% TTM, highlighting inefficiencies in generating returns for shareholders. The equity ratio stands at 70.84% TTM, indicating a strong equity base relative to total assets. Overall, while the company maintains a solid equity position, it struggles with profitability.

Cash Flow

Quanterix's cash flow statement indicates significant challenges. The company has a negative operating cash flow of -$65.09 million TTM, and free cash flow is also negative at -$68.22 million TTM. Despite a substantial free cash flow growth rate of 107.42% TTM, the operating cash flow to net income ratio is negative, reflecting cash flow issues. The free cash flow to net income ratio is positive at 1.11 TTM, suggesting some efficiency in converting net income to free cash flow, but overall cash flow management remains a concern.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	128.98M	135.44M	121.14M	105.52M	110.56M	86.38M
Gross Profit	65.87M	81.12M	73.00M	45.36M	64.77M	48.18M
EBITDA	-93.33M	-44.26M	-36.37M	-67.89M	-51.64M	-27.27M
Net Income	-95.66M	-38.53M	-28.35M	-99.57M	-55.55M	-31.53M
Balance Sheet
Total Assets	444.14M	406.53M	428.57M	433.58M	506.51M	271.05M
Cash, Cash Equivalents and Short-Term Investments	134.81M	289.12M	321.32M	338.74M	396.46M	181.58M
Total Debt	40.12M	37.37M	41.46M	44.10M	21.89M	30.80M
Total Liabilities	129.61M	76.50M	78.61M	75.65M	65.56M	64.92M
Stockholders Equity	314.53M	330.04M	349.96M	357.93M	440.95M	206.13M
Cash Flow
Free Cash Flow	-68.22M	-38.53M	-22.69M	-60.00M	-61.52M	-27.30M
Operating Cash Flow	-65.09M	-35.16M	-18.90M	-48.27M	-47.91M	-23.36M
Investing Cash Flow	74.18M	-82.27M	-148.40M	-11.21M	-6.34M	-626.00K
Financing Cash Flow	-145.00K	456.00K	2.69M	2.31M	270.80M	96.24M

Quanterix Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.26
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QTRX, the sentiment is Positive. The current price of 7.26 is above the 20-day moving average (MA) of 5.79, above the 50-day MA of 5.70, and above the 200-day MA of 5.82, indicating a bullish trend. The MACD of 0.45 indicates Negative momentum. The RSI at 74.10 is Negative, neither overbought nor oversold. The STOCH value of 94.52 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QTRX.

Quanterix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VMD	76 Outperform	$262.70M	20.90	10.53%	―	18.90%	29.22%
QTRX	61 Neutral	$242.09M	-2.86	-29.28%	―	-2.69%	-149.18%
NNOX	60 Neutral	$285.65M	―	-34.75%	―	15.19%	-3.32%
TLSI	54 Neutral	$343.25M	―	―	―	49.52%	19.34%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MASS	45 Neutral	$229.83M	―	-42.72%	―	4.49%	3.61%
OM	42 Neutral	$82.68M	―	-92.33%	―	4.65%	68.71%

Quanterix Corporate Events

Quanterix Q3 Earnings Call: Growth Amid Challenges

Quanterix Corporation’s recent earnings call painted a picture of robust revenue growth and strategic integration, despite facing challenges in certain market segments. The company demonstrated strong execution in revenue growth and successful integration of Akoya, contributing to a positive cash position and early momentum in diagnostics. However, declines in core Simoa revenue and weaknesses in U.S. academic and pharmaceutical markets, compounded by the ongoing government shutdown, pose challenges. Nevertheless, Quanterix is well-positioned for future growth with early commercial and cross-selling momentum.

Quanterix Reports Q3 2025 Financial Results

Quanterix Corporation is a leader in ultra-sensitive biomarker detection, advancing precision medicine through its Simoa technology and recent acquisition of Akoya Biosciences, enhancing its capabilities in disease research and diagnostics. In its latest earnings report for the third quarter of 2025, Quanterix reported a revenue increase of 12.3% year-over-year, reaching $40.2 million, despite challenging market conditions. The company highlighted significant integration milestones from its Akoya acquisition, aiming for $85 million in annualized synergies and cash flow break-even by 2026. Key financial metrics included a gross margin decline to 42.8% and an adjusted EBITDA loss of $11.9 million, primarily due to acquisition and restructuring costs. Quanterix ended the quarter with $138.1 million in cash and equivalents, projecting to close the year with approximately $120 million. Looking ahead, Quanterix maintains its revenue guidance for 2025 between $130 to $135 million, with expectations of achieving cash flow break-even in 2026, supported by continued growth in its Alzheimer’s diagnostics business and expanding partnerships in Asia.

Quanterix Approves Key Governance Changes at Annual Meeting

On September 29, 2025, Quanterix Corporation held its Annual Meeting of Stockholders, where several key proposals were approved. These included the election of three independent directors, approval of executive compensation, ratification of KPMG as the accounting firm, and amendments to the company’s Charter to declassify the board and eliminate supermajority voting requirements. These changes are expected to streamline governance and potentially enhance shareholder influence in corporate decisions.

The most recent analyst rating on (QTRX) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Quanterix stock, see the QTRX Stock Forecast page.